Trial reportScientific reports2024
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma.
Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The obesity-related chronic disease index (ORCDi), a novel composite metric to quantify ORCD burden: an ecological study across U.S. census tracts.Lancet regional health. Americas · 2026Article
- Sustained effects of auricular point acupressure on chemotherapy-induced neuropathy: a randomized controlled trial follow-up study.Journal of cancer survivorship : research and practice · 2026Article
- Article
- Longitudinal Symptom Recovery After Pancreatectomy: A Prospective Patient-Reported Outcomes Study using MDASI.Annals of surgical oncology · 2026Article
- Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-Surg.Annals of surgical oncology · 2026Article
- Patient symptoms, confidence, and adherence during the first 8 weeks of targeted oral anticancer agent treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Psychometric Validation of a new module of MD Anderson Symptom Inventory (MDASI) for Patients with Upper Gastrointestinal Cancers: MDASI-UGI-Surg.Annals of surgical oncology · 2026Article
- Defining critical symptom parameters for an ePRO-based management pathway during systemic treatment for advanced upper gastrointestinal cancer: a longitudinal study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Article
- Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies.Hematology. American Society of Hematology. Education Program · 2024Review
- Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.Journal of patient-reported outcomes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
We developed a composite symptom score (CSS) representing disease-related symptom burden over time in patients with malignant pleural mesothelioma (MPM). Longitudinal data were collected from an open-label Phase IIB study in which 239 patients completed the validated MD Anderson Symptom Inventory for MPM (MDASI-MPM). A blinded, independent review committee of external patient-reported outcomes experts advised on MDASI-MPM symptoms to include in the CSS. Through iterative analyses of potential symptom-item combinations, 5 MPM symptoms (pain, fatigue, shortness of breath, muscle weakness, coughing) were selected. The CSS correlated strongly with the full MDASI-MPM symptom set (0.92-0.94) and the Lung Cancer Symptom Scale-Mesothelioma (0.79-0.87) at each co-administration of the scales. The CSS also had good sensitivity to worsening disease and global quality-of-life ratings. The MDASI-MPM CSS can be used as an outcome in MPM clinical trials, including in responder analyses and at the individual patient level. It is brief enough to administer frequently, including electronically, to better capture symptom trajectories during and after a trial and in clinical practice. As a single score, the CSS addresses multiplicity issues that can arise when several symptoms increase due to worsening disease. Our process can be adapted to produce a CSS for other advanced-cancer trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.